Malignant tumor of parathyroid gland
diseaseOn this page
Also known as cancer of parathyroid glandmalignant neoplasm of parathyroidmalignant neoplasm of parathyroid glandmalignant neoplasm of the parathyroidmalignant neoplasm of the parathyroid glandmalignant parathyroid gland neoplasmmalignant parathyroid gland tumormalignant parathyroid gland tumourmalignant parathyroid neoplasmmalignant parathyroid tumormalignant parathyroid tumourmalignant tumor of parathyroidmalignant tumor of the parathyroidmalignant tumor of the parathyroid glandmalignant tumour of parathyroidmalignant tumour of the parathyroidmalignant tumour of the parathyroid glandparathyroid cancerparathyroid gland cancer
Summary
Malignant tumor of parathyroid gland (MONDO:0021311) is a cancer and 6 clinical trials. Top therapeutic interventions include trastuzumab, fluorocholine f-18, and edodekin alfa. A subtype of malignant endocrine neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | malignant tumor of parathyroid gland |
| Mondo ID | MONDO:0021311 |
| ICD-10-CM | C75.0 |
| NCIT | C9322 |
| SNOMED CT | 363481002 |
| UMLS | C0153653 |
| MedGen | 102283 |
| Anatomy (UBERON) | UBERON:0001132 |
| Is cancer (heuristic) | yes |
Also known as: cancer of parathyroid gland · malignant neoplasm of parathyroid · malignant neoplasm of parathyroid gland · malignant neoplasm of the parathyroid · malignant neoplasm of the parathyroid gland · malignant parathyroid gland neoplasm · malignant parathyroid gland tumor · malignant parathyroid gland tumour · malignant parathyroid neoplasm · malignant parathyroid tumor · malignant parathyroid tumour · malignant tumor of parathyroid · malignant tumor of the parathyroid · malignant tumor of the parathyroid gland · malignant tumour of parathyroid · malignant tumour of the parathyroid · malignant tumour of the parathyroid gland · parathyroid cancer · parathyroid gland cancer
Disease family
This is a subtype of malignant endocrine neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › malignant endocrine neoplasm › malignant tumor of parathyroid gland
Related subtypes (15): thyroid cancer, pituitary cancer, neuroendocrine carcinoma, ovarian neuroendocrine neoplasm, thymus cancer, liver cancer, adrenal gland cancer, pineal gland cancer, malignant carotid body paraganglioma, malignant jugulotympanic paraganglioma, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, high-grade neuroendocrine carcinoma of the corpus uteri, low-grade neuroendocrine tumor of the corpus uteri, maligant granulosa cell tumor of ovary
Subtypes (1): parathyroid gland carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07444723 | PHASE2/PHASE3 | RECRUITING | Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
| NCT04969926 | Not specified | RECRUITING | Natural History Study of Parathyroid Disorders |
| NCT00068497 | Not specified | COMPLETED | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer |
| NCT04299425 | Not specified | COMPLETED | Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy |
| NCT05022641 | Not specified | COMPLETED | Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TRASTUZUMAB | 4 | 1 |
| FLUOROCHOLINE F-18 | 3 | 1 |
| EDODEKIN ALFA | 2 | 1 |
Related Atlas pages
- Drugs: Trastuzumab, FLUOROCHOLINE F-18